Arun Sanyal

Professor of Medicine

Virginia Commonwealth University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Arun Sanyal is a Professor of Medicine at Virginia Commonwealth University in the United States. His research primarily focuses on metabolic dysfunction-associated steatosis and the implications of liver disease in the context of cardiometabolic health. Recent publications highlight his work on non-invasive testing for liver conditions and the development of AI tools for pathology in liver disease. He is also involved in exploring the psychological aspects affecting patients with liver conditions.

Articles (28)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (7)

Henning Grønbæk

Aarhus University

DENMARK

View details

Florence Wong

Professor

University of Toronto

CANADA

View details

David Kleiner

National Cancer Institute

UNITED STATES

View details

Quentin M. Anstee

Newcastle University

UNITED KINGDOM

View details

Raj Vuppalanchi

Professor of Medicine

Indiana University School of Medicine

UNITED STATES

View details

PIETRO ANDREONE

Professor of Medicine and Surgery

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia

ITALY

View details

Won Kim

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Arun Sanyal

Research Interests

Explore related searches

Contact this professor

About

Articles (28)

Proteomic signatures reflect effects of semaglutide treatment for MASH

Exploration of Multiple Non‐Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH

Publisher Correction: Integrating liver endpoints in clinical trials of cardiovascular and kidney disease

Tides of emotion: Hepatologists’ role in navigating depression and anxiety in liver disease

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH

Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events

Digital Pathology Quantification of the Continuum of Cirrhosis Severity in Human Liver Biopsies

MASLD as a non-communicable disease

A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis

Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis

Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology

Integrating liver endpoints in clinical trials of cardiovascular and kidney disease

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

Digital pathology for nonalcoholic steatohepatitis assessment

Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

NIS2+™, an effective blood-based test for the diagnosis of at-risk nonalcoholic steatohepatitis in adults 65 years and older

Editorial: Feeling better about NASH—Authors' reply

Improved health‐related quality of life with semaglutide in people with non‐alcoholic steatohepatitis: A randomised trial

The future of hepatology

The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure

Letter: non‐invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply

Collaborators (7)

Henning Grønbæk

Florence Wong

David Kleiner

Quentin M. Anstee

Raj Vuppalanchi

PIETRO ANDREONE

Won Kim

Make your next move.